Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL1735

INDINAVIR SULFATE
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O
ChEMBL ↗ Properties Compare Identifier

Basic Information

ChEMBL ID CHEMBL1735
Name INDINAVIR SULFATE
Phase Approved
Structure Type MOL
InChI Key NUBQKPWHXMGDLP-BDEHJDMKSA-N
Therapeutic ✓ Yes
Parent Compound CHEMBL115
Active Moiety CHEMBL115

Known Names

Crixivan Indinavir sulfate Indinavir sulfate ethanolate Indinavir sulphate Indinaviri sulfas L-735,524 L-735524 MK-639 NSC-697197
5
Targets
10
Activities
2
Assay Types
0
PK Parameters
20
Publications
9
Known Names
7
Indications
2
Mechanisms

Molecular Properties

613.8
MW (Da)
2.87
ALogP
7
HBA
4
HBD
118.0
PSA (Ų)
0.26
QED
1
Ro5 Violations
11
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 1996
Availability Discontinued
Chirality Single Enantiomer

Routes of Administration

Oral
USAN Stem -vir
USAN Year 1995

Extended Properties

Molecular Formula C36H49N5O8S
MW 711.88
Aromatic Rings 3
Heavy Atoms 45
NP-Likeness -0.42

Mechanism of Action

Mechanism Action Type Target Direct Efficacy
Human immunodeficiency virus type 1 protease inhibitor INHIBITOR Human immunodeficiency virus type 1 protease ✓ ✓
Human immunodeficiency virus type 1 protease inhibitor INHIBITOR Human immunodeficiency virus type 1 protease ✓ ✓

Indications

HIV Infections Mycobacterium avium-intracellulare Infection Neoplasms Rhabdomyosarcoma Sarcoma Sarcoma, Ewing Hypertension

Activity Summary

EC50 8 meas. best 8.26
IC50 2 meas. best 9.39

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
Human immunodeficiency virus type 1 protease
CHEMBL243
 IC50 9.39 9.39 0.4 1
Human immunodeficiency virus 1
CHEMBL378
 EC50 8.26 8.108 5.5 5
HIV-1 M:B_Lai
CHEMBL612775
 EC50 8.06 8.06 8.7 1
Human T-cell leukemia virus type I
CHEMBL613551
 IC50 7.66 7.66 22.0 1
Nuclear receptor subfamily 1 group I member 2
CHEMBL3401
 EC50 4.85 4.825 14100.0 2

Activity Data Samples

Top measurements by pChEMBL value

Target Type Rel. Value Units pChEMBL Assay PubMed
Human immunodeficiency virus type 1 protease IC50 = 0.41 nM 9.39 Inhibition of HIV-1 protease in vitro. 10978186
Human immunodeficiency virus 1 EC50 = 5.5 nM 8.26 Antiviral activity against HIV1 LAI infected in human C8166 cells assessed as in... 18855443
Human immunodeficiency virus 1 EC50 = 8.18 nM 8.09 Inhibition of HIV1 LAI replication in C8166 cells after 4 days by ELISA 18303847
Human immunodeficiency virus 1 EC50 = 8.2 nM 8.09 Antiviral activity against HIV1 infected human C8166 cells assessed as inhibitio... 19618920
HIV-1 M:B_Lai EC50 = 8.71 nM 8.06 Antiviral activity against HIV-1 M:B_Lai replication in human C8166 cells assess... 19326880
Human immunodeficiency virus 1 EC50 = 8.81 nM 8.05 Antiviral activity against HIV1 in human C8116 cells assessed as reduction of p2... 18468908
Human immunodeficiency virus 1 EC50 = 8.81 nM 8.05 Antiviral activity against HIV1 replication in human C8166 cells by ELISA 19101157
Human T-cell leukemia virus type I IC50 = 22.0 nM 7.66 Antiviral activity against HTLV1 3B infected in human MT4 cells assessed as reve... 17950955
Nuclear receptor subfamily 1 group I member 2 EC50 = 14100.0 nM 4.85 Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by l... 20966043
Nuclear receptor subfamily 1 group I member 2 EC50 = 15800.0 nM 4.8 Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induc... 20966043

Literature References

PubMed DOI Target Context # Activities
20966043 10.1124/dmd.110.035105 Nuclear receptor subfamily 1 group I member 2 6
17950955 10.1016/j.ejmech.2007.08.016 Caco-2 4
10978186 10.1021/jm9903848 Human immunodeficiency virus type 1 protease 2
18855443 10.1021/np800357g Human immunodeficiency virus 1 1
- 10.6019/CHEMBL4513141 Staphylococcus aureus 1
- 10.6019/CHEMBL4513141 Pseudomonas aeruginosa 1
- 10.6019/CHEMBL4513141 Klebsiella pneumoniae 1
- 10.6019/CHEMBL4513141 Escherichia coli 1
- 10.6019/CHEMBL4513141 Cryptococcus neoformans 1
- 10.6019/CHEMBL4513141 Candida albicans 1
- 10.1101/2020.04.03.023846 SARS-CoV-2 1
20843939 10.1124/dmd.110.035113 Hepatotoxicity 1
19618920 10.1021/np900308s Human immunodeficiency virus 1 1
19326880 10.1021/np900116m HIV-1 M:B_Lai 1
17950955 10.1016/j.ejmech.2007.08.016 MT4 1
17950955 10.1016/j.ejmech.2007.08.016 Human T-cell leukemia virus type I 1
17950955 10.1016/j.ejmech.2007.08.016 CEM-SS 1
17950955 10.1016/j.ejmech.2007.08.016 Human immunodeficiency virus 1 1
19101157 10.1016/j.bmc.2008.11.066 Human immunodeficiency virus 1 1
18468908 10.1016/j.bmc.2008.04.052 Human immunodeficiency virus 1 1

Data from ChEMBL 36 via Core Engine